XNAS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$170.87+0.92%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
41/100
Weak
Score components
TickerWhale View
Gilead Sciences scores 41 out of 100 overall, which we rate weak. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%6Weak
- Revenue growth 5.5%
- EPS growth -153.3%
Valuation
25%20Weak
- P/E -65.6
- EV/Sales 7.7
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
#55 by market cap in our coverage · ~17,000 employees · Listed 1992-01-22 · www.gilead.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#120 / 139sector rank by TickerWhale Score
TickerWhale Score 41 vs sector average 54.6 (-13.6)
Revenue growth (industry)Top 55%
Gross margin (industry)Top 27%
Return on equity (industry)Top 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
98/100Strong vs universe
Ranks 98th of 100 covered names on our technical composite — the composite itself scores 86/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
5 buy · 0 sell · 3 neutral of 8 votes
TickerWhale rates GILD's technical setup strong — 98th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+20.9%
- vs 50-day+11.0%
Momentum
Mixed
- RSI (14)64 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength34· trending
- MACD (12,26,9)buy(histogram 0.491)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 0 sell · 3 neutral.
Result — 5 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-65.6 · TTM loss
- P/S (TTM)7.0
- P/B18.0
- EV/EBITDA—
- EV/Sales7.7
- PEG—
Profitability & returns
- Gross margin79.6%
- Net margin-10.6%
- ROE-18.3%
- Debt/Equity2.22
Growth
- Revenue growth (YoY)5.5%
- EPS growth (YoY)-153.3%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $212.4B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B |
| Gross profit | $23.2B | $22.5B | $20.6B |
| Operating income | $10.0B | $1.7B | $7.6B |
| Net income | $8.5B | $480M | $5.7B |
| EPS (diluted) | $6.78 | $0.38 | $4.50 |
| Free cash flow | $9.5B | $10.3B | $7.4B |
| Cash | $7.6B | $10.0B | $6.1B |
| Total debt | $24.9B | $26.7B | $25.0B |
| Equity | $22.7B | $19.3B | $22.8B |
| Net debt | $17.4B | $16.7B | $18.9B |
| Debt / equity | 1.10 | 1.38 | 1.09 |
| Liabilities / assets | 0.62 | 0.67 | 0.63 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILDCurrentGilead Sciences | 41 | 86 | -65.6 | — | 18.0 | 7.7 | $170.87 | +0.92% | +5.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.